| MeSH term | MeSH ID | Detail |
|---|---|---|
| Inflammation | D007249 | 119 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Brain Ischemia | D002545 | 89 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Atherosclerosis | D050197 | 85 associated lipids |
| Hyperlipidemias | D006949 | 73 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Asthma | D001249 | 52 associated lipids |
| Thrombosis | D013927 | 49 associated lipids |
11-dehydro-txb2
Cross Reference
Introduction
To understand associated biological information of 11-dehydro-txb2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 11-dehydro-txb2?
11-dehydro-txb2 is suspected in Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis, Chronic ischemic heart disease NOS, Diabetes Mellitus, Diabetes Mellitus, Non-Insulin-Dependent and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 11-dehydro-txb2
PubChem Associated disorders and diseases
What pathways are associated with 11-dehydro-txb2
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 11-dehydro-txb2?
There are no associated biomedical information in the current reference collection.
What functions are associated with 11-dehydro-txb2?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 11-dehydro-txb2?
There are no associated biomedical information in the current reference collection.
What genes are associated with 11-dehydro-txb2?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 11-dehydro-txb2?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with 11-dehydro-txb2
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Minuz P et al. | Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. | 2002 | Circulation | pmid:12451006 |
| Bruno A et al. | Aspirin and urinary 11-dehydrothromboxane B(2) in African American stroke patients. | 2002 | Stroke | pmid:11779889 |
| Obase Y et al. | Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. | 2002 | Chest | pmid:11796443 |
| Cipollone F et al. | Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. | 2002 | Circulation | pmid:12135935 |
| Eikelboom JW et al. | Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. | 2002 | Circulation | pmid:11940542 |
| Hayashi M et al. | Characterization of five marker levels of the hemostatic system and endothelial status in normotensive pregnancy and pre-eclampsia. | 2002 Nov-Dec | Eur. J. Haematol. | pmid:12460234 |
| Davì G et al. | Platelet activation in obese women: role of inflammation and oxidant stress. | 2002 Oct 23-30 | JAMA | pmid:12387653 |
| Tanaka S et al. | High dose of inhaled fluticasone reduces high levels of urinary leukotriene E4 in the early morning in mild and moderate nocturnal asthma. | 2003 | Chest | pmid:14605047 |
| Bosetti F et al. | Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. | 2003 | J. Neurochem. | pmid:12694395 |
| Wolfram R et al. | Daily prickly pear consumption improves platelet function. | 2003 | Prostaglandins Leukot. Essent. Fatty Acids | pmid:12878452 |
| De Cristofaro R et al. | Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. | 2003 | J. Thromb. Haemost. | pmid:12871497 |
| Davì G et al. | Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. | 2003 | Circulation | pmid:12810609 |
| Cipollone F et al. | Modulation of aspirin-insensitive eicosanoid biosynthesis by 6-methylprednisolone in unstable angina. | 2003 | Circulation | pmid:12515743 |
| Tsuruta LR et al. | Characterization of 11-dehydro-thromboxane B2 recombinant antibody obtained by phage display technology. | 2003 | Prostaglandins Leukot. Essent. Fatty Acids | pmid:12628223 |
| Hart RG et al. | Aspirin dosage and thromboxane synthesis in patients with vascular disease. | 2003 | Pharmacotherapy | pmid:12741431 |
| Böhm E et al. | 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. | 2004 | J. Biol. Chem. | pmid:14668348 |
| Suzuki N et al. | Quantitative liquid chromatography-tandem mass spectrometric analysis of 11-dehydro TXB2 in urine. | 2004 | Prostaglandins Other Lipid Mediat. | pmid:15165035 |
| Perneby C et al. | Prothrombotic responses to exercise are little influenced by clopidogrel treatment. | 2004 | Thromb. Res. | pmid:15381386 |
| Hennekens CH et al. | Terms and conditions: semantic complexity and aspirin resistance. | 2004 | Circulation | pmid:15381661 |
| Ferroni P et al. | Platelet activation in type 2 diabetes mellitus. | 2004 | J. Thromb. Haemost. | pmid:15304032 |
| Bruno A et al. | Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. | 2004 | Stroke | pmid:14963281 |
| Minuz P et al. | Determinants of platelet activation in human essential hypertension. | 2004 | Hypertension | pmid:14656953 |
| Vainio M et al. | Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders. | 2004 | Acta Obstet Gynecol Scand | pmid:15548142 |
| Capone ML et al. | Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. | 2004 | Circulation | pmid:15037526 |
| Ikonomidis I et al. | Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor. | 2004 | Heart | pmid:15020512 |
| Dippel DW et al. | What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? | 2004 | Cerebrovasc. Dis. | pmid:15026612 |
| Ikonomidis I et al. | Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. | 2005 | Am. Heart J. | pmid:15894964 |
| Coppola A et al. | Reduced in vivo oxidative stress following 5-methyltetrahydrofolate supplementation in patients with early-onset thrombosis and 677TT methylenetetrahydrofolate reductase genotype. | 2005 | Br. J. Haematol. | pmid:16173969 |
| Haubelt H et al. | Can platelet function tests predict the clinical efficacy of aspirin? | 2005 | Semin. Thromb. Hemost. | pmid:16149017 |
| Davì G et al. | Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. | 2005 | Arterioscler. Thromb. Vasc. Biol. | pmid:15472127 |
| Kataoka M et al. | A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. | 2005 | Am. J. Respir. Crit. Care Med. | pmid:16192456 |
| Saloheimo P et al. | Thromboxane and prostacyclin biosynthesis in patients with acute spontaneous intracerebral hemorrhage. | 2005 | Thromb. Res. | pmid:15733969 |
| De Candia E et al. | Abnormal pH-sensing of platelet Na+/H+ exchanger in patients with cardiac syndrome X. | 2005 | Int. J. Cardiol. | pmid:15837078 |
| Sciulli MG et al. | Platelet activation in patients with colorectal cancer. | 2005 | Prostaglandins Leukot. Essent. Fatty Acids | pmid:15626589 |
| Gonzalez-Conejero R et al. | Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? | 2005 | Stroke | pmid:15604423 |
| Falco A et al. | Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus. | 2005 | Atherosclerosis | pmid:16285996 |
| Baltzer WI et al. | Measurement of urinary 11-dehydro-thromboxane B2 excretion in dogs with gastric dilatation-volvulus. | 2006 | Am. J. Vet. Res. | pmid:16426215 |
| Faraday N et al. | Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. | 2006 | Am. J. Cardiol. | pmid:16950183 |
| Renda G et al. | Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. | 2006 | Clin. Pharmacol. Ther. | pmid:16952493 |
| Markuszewski L et al. | Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin? | 2006 | Basic Clin. Pharmacol. Toxicol. | pmid:16635110 |
| Laleman W et al. | A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. | 2006 | Eur. J. Clin. Invest. | pmid:16620286 |
| Ohmori T et al. | Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. | 2006 | J. Thromb. Haemost. | pmid:16706971 |
| Santilli F et al. | Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. | 2006 | J. Am. Coll. Cardiol. | pmid:16412866 |
| Ciabattoni G et al. | Determinants of platelet activation in Alzheimer's disease. | 2007 | Neurobiol. Aging | pmid:16442186 |
| Chakroun T et al. | Screening for aspirin resistance in stable coronary artery patients by three different tests. | 2007 | Thromb. Res. | pmid:17553552 |
| Maree AO and Fitzgerald DJ | Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. | 2007 | Circulation | pmid:17452618 |
| Schwartz JI et al. | Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. | 2007 | J Clin Pharmacol | pmid:17925592 |
| Heistein LC et al. | Aspirin resistance in children with heart disease at risk for thromboembolism: prevalence and possible mechanisms. | 2008 | Pediatr Cardiol | pmid:17896127 |
| Patrignani P et al. | Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. | 2008 | Pharmacogenet. Genomics | pmid:18551041 |
| Geske FJ et al. | AspirinWorks: a new immunologic diagnostic test for monitoring aspirin effect. | 2008 | Mol Diagn Ther | pmid:18288882 |